Asvasiran API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Asvasiran | CAS No: 870094-26-1 | GMP-certified suppliers
A medication that targets viral infections by inhibiting respiratory syncytial virus replication, supporting development in infectious and parasitic disease treatment.
Primary indications
- Investigated for use/treatment in infectious and parasitic disease (unspecified) and viral infection
Product Snapshot
- Asvasiran is an investigational oligonucleotide therapeutic
- It is studied primarily for treatment of infectious, parasitic, and viral diseases
- The compound is currently in the investigational stage without regulatory approval
Clinical Overview
The therapeutic potential of asvasiran is primarily focused on the treatment or prevention of RSV infection, a leading cause of respiratory illness particularly in infants, young children, and immunocompromised individuals. Although it is currently under investigation, asvasiran represents a novel antiviral approach by utilizing RNA interference technology to disrupt essential viral gene expression.
Pharmacodynamic and detailed pharmacokinetic data have not been disclosed, and the absorption, distribution, metabolism, and excretion (ADME) profile of asvasiran remains to be fully characterized. Given its siRNA nature, delivery mechanisms and stability in biological matrices are critical factors influencing its bioavailability and therapeutic effectiveness.
Safety and toxicity profiles have not been extensively reported. As with other oligonucleotide therapeutics, potential concerns may include immunogenicity, off-target effects, and delivery-related toxicities. Careful evaluation in clinical trials is essential to define its safety margins and tolerability.
Currently, asvasiran is classified as an investigational compound without regulatory approval for clinical use. No branded products or marketed formulations are available at this time.
For pharmaceutical development and API procurement, it is important to ensure that asvasiran batches meet rigorous quality standards, including characterization of sequence integrity, purity, and absence of contaminants. Stability and handling conditions should also be closely monitored given the sensitivity of RNA-based molecules. Suppliers with expertise in nucleic acid synthesis and stringent quality systems are preferred to support further clinical and commercial development efforts.
Identification & chemistry
| Generic name | Asvasiran |
|---|---|
| Molecule type | Biotech |
| CAS | 870094-26-1 |
| UNII | 73X0VEC10T |
| DrugBank ID | DB05638 |
Formulation & handling
- Asvasiran is a biotech solid API intended primarily for injectable formulations due to its peptide nature.
- Handling should consider potential sensitivity to temperature and moisture to maintain stability.
- As an investigational biologic, formulation must ensure protection from enzymatic degradation and maintain bioactivity.
Regulatory status
Asvasiran is a type of Respiratory Tract Agents
Respiratory Tract Agents are a vital category of pharmaceutical APIs (Active Pharmaceutical Ingredients) designed to treat respiratory conditions and diseases. These agents are specifically formulated to target the respiratory system, which includes the lungs, airways, and nasal passages. They play a crucial role in managing various respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
Respiratory Tract Agents encompass a wide range of medications, including bronchodilators, corticosteroids, antihistamines, and mucolytics. Bronchodilators are commonly used to relieve airway constriction and facilitate smooth breathing by relaxing the muscles in the airways. Corticosteroids help reduce inflammation in the respiratory system, alleviating symptoms and preventing exacerbations. Antihistamines work by blocking histamine receptors, thus mitigating allergic reactions that often impact the respiratory tract. Mucolytics aid in loosening and thinning mucus, making it easier to expel from the airways.
These APIs are developed through rigorous research and development processes, ensuring their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers rely on advanced technologies and stringent quality control measures to produce high-quality Respiratory Tract Agents. These APIs are subsequently incorporated into various dosage forms, including inhalers, nasal sprays, nebulizers, and oral medications.
Respiratory Tract Agents are essential in the management of respiratory conditions, providing relief from symptoms, improving lung function, and enhancing the overall quality of life for patients. They are prescribed by healthcare professionals and often used in combination therapies to achieve optimal results. As respiratory disorders continue to affect a significant portion of the global population, the development and availability of effective Respiratory Tract Agents play a vital role in addressing these health challenges and improving patient outcomes.
